Add to Basket
|+1 404 474 4654|
|+1 888 205 9894 (TF)|
Amyloid beta (Abeta) (N-Term) antibody (Biotin)
|Synonyms||AAA, AD1, PN2, ABPP, APPI, CVAP, ABETA, CTFgamma, aaa, ad1, pn2, abpp, appi, cvap, abeta, MGC88882, ctfgamma, APP|
Alternatives Immunohistochemistry (IHC), Western Blotting (WB)
|11 references available|
|Price||618.20 $ Plus shipping costs $45.00|
|Availability||Will be delivered in 8 to 11 Business Days|
|Alternative name||Amyloid beta (N) (82E1) biotinylated|
|Immunogen||Synthetic peptide for Human Amyloid (1-16) (DAEFRHDSGYEVHHQK)|
|Description||Alzheimer's disease (AD) is characterized by the presence of extracellular plaques and intracellular neurofibrillary tangles (NFTs) in the brain. The major protein component of these plaques is beta amyloid peptide (A), a 40 to 43 amino acid peptide cleaved from amyloid precursor protein by -secretase and -secretase. Increased release of A42 or A43, both of which exibit a greater tendency to aggregate than A40, occurs in individuals expressing certain genetic mutations, ApoE alles or may involve other undiscovered factors. Many researchers theorize that it is this increased release of A42/A43 which leads to the abnormal deposition of A and the associated neurotoxicity in the brains of affected individuals. This antibody is biotinylated antibody, therefore, the antibody can be useful for immunohistochemistry and western blotting applications to APP transgenic mice such as Tg2576.|
|Specificity||Human A and -CTF N-terminal specific. Reacts with both soluble and fibrillar A to a similar degree. Nonreactivities with non-cleaved APP. Very low crossreactivities with mouse and rat A (<10%).|
|Application Notes||This antibody can be stained in formalin fixed paraffin embedded tissues after formic acid treatment*1 by several Immunohistochemical techniques such as Avidin Biotin Complex (ABC) Method. The optimal dilution is 1 ug /mL, however, the dilution rate should be optimized by each laboratories. *1: rinsing by running water after formic acid treatment for 5 minutes following de-paraffin. For western blotting the antibody may be diluted to 1:1000.|
|Buffer||Lyophilized product from 1% BSA in PBS containing 0.05% NaN3 Reconstitution: 0.5mL distilled water will be added to the product (The conc. comes up 100 ug /mL)|
|Storage||Lyophilized product, 5 years at 2° to 8° Celsius.|
|Research Area||Alzheimer's Disease|
|Restrictions||For Research Use only|
Smirnov, Trupp, Henkel et al.: "Differential processing and secretion of Abeta peptides and sAPPalpha in human platelets is regulated by thrombin and prostaglandine 2." in: Neurobiology of aging, Vol. 30, Issue 10, pp. 1552-62, 2009 (PubMed).
Hirata-Fukae, Li, Hoe et al.: "Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model." in: Brain research, Vol. 1216, pp. 92-103, 2008 (PubMed).
Kim, Miller, Levites et al.: "BRI2 (ITM2b) inhibits Abeta deposition in vivo." in: The Journal of neuroscience : the official journal of the Society for Neuroscience, Vol. 28, Issue 23, pp. 6030-6, 2008 (PubMed).
Spencer, Marr, Rockenstein et al.: "Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice." in: BMC neuroscience, Vol. 9, pp. 109, 2008 (PubMed).
Adachi, Kano, Saido et al.: "Visual screening and analysis for kinase-regulated membrane trafficking pathways that are involved in extensive beta-amyloid secretion." in: Genes to cells : devoted to molecular & cellular mechanisms, Vol. 14, Issue 3, pp. 355-69, 2009 (PubMed).
Lakshmana, Yoon, Chen et al.: "Novel role of RanBP9 in BACE1 processing of amyloid precursor protein and amyloid beta peptide generation." in: The Journal of biological chemistry, Vol. 284, Issue 18, pp. 11863-72, 2009 (PubMed).
Achim, Adame, Dumaop et al.: "Increased accumulation of intraneuronal amyloid beta in HIV-infected patients." in: Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, Vol. 4, Issue 2, pp. 190-9, 2009 (PubMed).
Roennbaeck, Zhu, Dillner et al.: "Progressive neuropathology and cognitive decline in a single Arctic APP transgenic mouse model." in: Neurobiology of aging, 2009 (PubMed).
Philipson, Lannfelt, Nilsson: "Genetic and pharmacological evidence of intraneuronal Abeta accumulation in APP transgenic mice." in: FEBS letters, Vol. 583, Issue 18, pp. 3021-6, 2009 (PubMed).
Yamada, Yabuki, Seubert et al.: "Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta." in: The Journal of neuroscience : the official journal of the Society for Neuroscience, Vol. 29, Issue 36, pp. 11393-8, 2009 (PubMed).
Takami, Nagashima, Sano et al.: "gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment." in: The Journal of neuroscience : the official journal of the Society for Neuroscience, Vol. 29, Issue 41, pp. 13042-52, 2009 (PubMed).